Legal Representation
Attorney
Douglas T. Johnson
USPTO Deadlines
Next Deadline
1721 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-04-09)
Due Date
April 09, 2030
Grace Period Ends
October 09, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
29 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jan 17, 2025 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Jan 1, 2025 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Dec 31, 2024 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Oct 19, 2024 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Apr 9, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Apr 9, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jan 23, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jan 23, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jan 22, 2024 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Jan 3, 2024 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Jan 3, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 3, 2024 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Dec 18, 2023 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 12, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Dec 12, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 12, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 12, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Dec 8, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 7, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 7, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 26, 2023 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Jul 1, 2023 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Jul 1, 2023 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| May 20, 2023 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| May 19, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 18, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 28, 2023 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Feb 24, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Feb 23, 2023 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Viral systems comprised of viral vectors combined with antibodies; gene therapy systems comprised of viral vectors combined with antibodies; nucleic acid delivery systems being therapeutic agents for delivery to human tissue namely viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors for medical purposes; pharmaceutical products for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for the treatment neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; clinical medical reagents for use in nucleic acid-based therapy, cell therapy, pharmaceutical preparations, prophylaxis products preparations and other pharmaceutical products preparations and other pharmaceutical products preparations for use in nucleic acid-based therapy, gene therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases
Class 042
Scientific and medical research, product development and consultancy in the field of biotechnology, biologics, medical science, chemistry and biochemistry; Scientific and medical research and product development in the field of pharmaceutics
Class 044
Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders; consultancy in the field of pharmaceutics
Classification
International Classes
005
042
044